Compare SNOA & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | SNGX |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.6M |
| IPO Year | 2006 | 2006 |
| Metric | SNOA | SNGX |
|---|---|---|
| Price | $1.37 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 171.9K | ★ 224.8K |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.26 | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,529,000.00 | $119,371.00 |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $24.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.68 | N/A |
| 52 Week Low | $0.85 | $0.28 |
| 52 Week High | $5.60 | $6.23 |
| Indicator | SNOA | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 51.64 |
| Support Level | $1.03 | $0.37 |
| Resistance Level | $3.88 | $0.41 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 78.95 | 79.76 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).